<DOC>
	<DOC>NCT02149420</DOC>
	<brief_summary>This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of a single intravenous infusion of VAY7346 monoclonal antibody in pSS patients</brief_summary>
	<brief_title>PD of VAY736 in Patients With Primary Sjögren's Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Sjogren's Syndrome</mesh_term>
	<criteria>INCLUSION CRITERIA: Fulfilled revised European US consensus criteria for pSS ESSDAI value ≥ 6 Elevated serum titers at screening of ANA (≥ 1:160) Seropositive at screening for antiSSA and/or antiSSB antibodies Stimulated whole salivary flow rate at screening of &gt; 0 mL/min EXCLUSION CRITERIA: Prior or previous use of (specific dosages and intervals prior to study start may apply): Bcell depleting therapy (e.g., rituximab), Prednisone, antiBAFF mAb, CTLA4Fc Ig (abatacept), antiTNFα mAb, cyclophosphamide, azathioprine and medications known to cause dry mouth. Hydroxychloroquine or methotrexate in a consistent dose for ≥ 3 months prior to randomization is allowed Active or recent history of clinically significant infection Vaccination within 2 month prior to study History of primary or secondary immunodeficiency Other protocoldefined inclusion/exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>primary Sjögren's syndrome, pharmacodynamics</keyword>
</DOC>